Disc Medicine, Inc.

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

President-elect Donald Trump’s plan to nominate Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services was not entirely unexpected, but it sent biopharmaceutical stock va

The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three

Disc Medicine, Inc. presented Phase II data for bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) showing consistent and sustained suppression of a metabolite that c